Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib

Takeda, Takayuki; Yamada, Tadaaki; Tanimura, Keiko; Nakano, Takayuki; Ishida, Masaki; Tachibana, Yusuke; Shiotsu, Shinsuke; Horiuchi, Shigeto; Hibino, Makoto; Okada, Asuka; Chihara, Yusuke; Takayama, K.

doi:10.3390/diagnostics11122170

Cited by 9 publications

(7 citation statements)

References 42 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study of the Chinese Academy of Medical Sciences confirmed that in ALK -positive NSCLC patients treated with crizotinib, the trend of NLR, derived NLR [dNLR = neutrophil count/(white blood cell count-neutrophil count)], PLR, and HGB can be used to assess a patient’s progress ( 15 ). A Japanese study noted that immunological and nutritional markers could be useful in predicting the outcomes of first-line treatment with alectinib ( 32 ). In our study, NLR was not only an independent prognostic factor in univariate and multivariate analysis, but also changes in NLR before and after treatment can reflect the efficacy and be used to further predict survival.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study

Jiang¹,

Shi²,

Liu³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: Alectinib is a second generation of ALK-tyrosine kinase inhibitors (ALK-TKIs), which has attracted much attention in the treatment of ALK-positive non-small cell lung cancer (NSCLC). At present, there are few reports on the efficacy and safety of alectinib in Chinese population. Moreover, biomarkers reflecting prognosis and efficacy are exceedingly needed. This study assessed the efficacy of alectinib in patients with ALK-positive NSCLC and analyzed the prognostic factors. Methods: Patients with ALK-positive NSCLC who were confirmed by histopathology or cytology at the Affiliated Cancer Hospital of Nanjing Medical University between October 2018 and October 2021 were enrolled. All patients were treated with alectinib. The clinical characteristics and circulating tumor biomarkers before and after treatment were collected. Kaplan-Meier test was used to calculate the progression-free survival (PFS). Univariate and multivariate Cox regression analyses were used to explore the influencing factors on PFS. Incidence of adverse events was observed. Results: Twenty patients progressed after first-line treatment (n=59) with alectinib, and 21 patients progressed following second-line treatment (n=36) with alectinib. The median PFS of first-line treatment patients was not achieved, and the median PFS of patients undergoing second-line treatment was 15.0 months ^ ORCID:

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study

Jiang¹,

Shi²,

Liu³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…16 studies with 2378 patients(16-18, 21,22,27,30,32,34,36,37,39,41,42,44,47) showed an association between the SII and PFS in NSCLC. Heterogeneity was signi cant (I 2 = 83.1%, P < 0.001), and a random-effects model was performed.…”

Section: Sii and Pfs In Nsclcmentioning

confidence: 99%

“…Subsequently, 13 studies were eliminated because 9 studies did not provide survival data, full-text articles of 2 studies were not available, and 2 studies were comments. Finally, a total of 32 studies involving 12,040 patients were included 47). (Fig.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…The included studies were all retrospective and published during 2017-2023, with a sample size between 34 and 3984. One of the 9 studies was conducted in non-Asian (17,22,27,30,33,35,36,42,47), and the others were conducted in China (14-16, 18-21, 23-26, 28, 29, 31, 32, 34, 37-41, 43, 44). The SII cut-off values ranged from 395.4 to 1,270.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic role of the systemic immune-inflammation in patients with non-small cell lung cancer: a meta-analysis

Zhao

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background:Systemic immune-inflammation (SII) has been identified as an independent prognostic factor for many types of cancer. However, there is controversy regarding the prognostic value of SII in assessing non-small cell lung cancer (NSCLC) prognosis. Methods:In this study, we conducted a comprehensive search of the electronic databases of PubMed, Embase, and Cochrane Library up to March 21, 2023, to evaluate the prognostic value of SII in NSCLC. We calculated the hazard ratio (HR) and 95% confidence interval (CI) to assess the relationship between SII and overall survival (OS) or progression-free survival (PFS). Results: Our analysis included 32 studies involving 12,040 patients. The results showed that increased SII was significantly associated with poor OS (HR, 1.31; 95% CI, 1.21-1.41; p<0.001) and PFS (HR, 1.48; 95% CI 1.12-1.94; p<0.001) in NSCLC patients. Subgroup analysis further confirmed these findings. Sensitivity analysis and publication bias results indicated the stability of the results. Conclusions:Our study demonstrates that high SII is a significant predictor of poor OS and PFS in NSCLC patients. Therefore, SII may serve as a useful tool to evaluate the prognosis of NSCLC and guide the development of treatment strategies.

show abstract

“…In the case of ALK mutation in patients with non-small cell lung cancer who received appropriate first-line targeted therapy, the duration of PFS was determined to be associated with baseline PLR, and SII, as well as the SII, score three weeks after initiation of therapy. Indexes were measured before and three weeks after drug administration [18]. Ju et al found that lower SII was associated with prolonged survival in patients with different EGFR mutant lung adenocarcinomas.…”

Section: Figure 1 -Roc Curve Analysis For Optimal Cut-off Value Of In...mentioning

confidence: 99%

Inflammation Indexes as Predictors of Recurrence in Patients With Surgically Resected Non-Small Cell Lung Cancer

Smorodska

Moskalenko

Kononenko

et al. 2022

EUMJ

View full text Add to dashboard Cite

Introduction. Prediction of lung cancer recurrence is one of the most urgent problems of modern oncology. Scientists are trying to find independent predictors that will help intensify, personalize the patient's treatment, and prevent the disease relapse on time. The study aimed to find indicators of inflammation that could be independent predictors of disease recurrence in patients with surgically resected non-small cell lung cancer. Materials and methods. The study was conducted retrospectively. The study group included 104 patients with non-small cell lung cancer who received surgical treatment and adjuvant chemotherapy or chemoradiotherapy from 2014 to 2018 at the Sumy Regional Clinical Oncology Dispensary. Based on the results of the blood count tests, the inflammation indices were calculated before chemotherapy or chemoradiotherapy and one month after their completion. Systemic inflammatory response index (SIRI), systemic inflammatory index (SII), neutrophil/lymphocyte ratio (NLR), platelets/lymphocytes ratio (PLR), lymphocyte/monocyte ratio (LMR), monocyte/lymphocyte ratio (MLR) were calculated. Using ROC analysis, cut-off points were found. Cox regression was used to find independent predictors of lung cancer recurrence. Results. During the observation period, relapse of the disease was recorded in 42 (40.4%) patients. The average recurrence-free survival was 56.3 months, range of 4–84.0 months (95% CI = 46.866–65.683). Before chemo- or chemoradiation therapy, the cut-off points for NLR1, PLR1, MLR1, LMR1, SII1, and SIRI1 were 1.80, 126.35, 0.22, 4.80, 521.22 and 0.96, respectively. Cut-off points for NLR2, PLR2, MLR2, LMR2, SII2, and SIRI2 at stage one month after completing courses of chemotherapy or chemoradiotherapy were 1.33, 153.80, 0.26, 3.98, 450.10 and 0.82 respectively. According to ROC analysis, only PLR1, SII1, LMR1, and LMR2 indices are reliable and can be used in further Cox regression analysis. Univariant Cox regression showed that LMR1 and SII1 were significantly associated with disease recurrence. Multivariate Cox regression identified SII1 as the only independent predictor of disease recurrence. Conclusions. Among numerous inflammation indices as an independent predictor for disease recurrence in non-small cell lung cancer patients who received surgical treatment and chemotherapy or chemoradiotherapy, only systemic inflammation index (SII1) at the stage before chemotherapy or chemoradiotherapy can be used. Indicators above 521.22 could be a predictor of high-risk recurrence of lung cancer.

show abstract

Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib

Cited by 9 publications

References 42 publications

Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study

Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study

Prognostic role of the systemic immune-inflammation in patients with non-small cell lung cancer: a meta-analysis

Inflammation Indexes as Predictors of Recurrence in Patients With Surgically Resected Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About